Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Abgrall

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
HIV Medicine|December 4, 2018
Does region of origin influence the timing and outcome of first-line antiretroviral therapy in France?C Gatey, A Brun, G Hamet, et al.
International Journal of STD & AIDS|March 27, 2014
Risk factors for adherence failure in HIV-infected sub-Saharan migrants living in France and travelling back to their native countryS Abgrall, L Fugon, N Lélé, et al.
The Journal of Antimicrobial Chemotherapy|June 4, 2011
Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavirT Bommenel, O Launay, J L Meynard, et al.
HIV Medicine|November 5, 2024
Viral rebound on antiretroviral therapy in France according to region of origin, sex, and HIV acquisition group. Results from the French Hospital Database on HIV (ANRS CO4-FHDH)S Abgrall, H Selinger-Leneman, E Lanoy, et al.
Tuberculosis (Edinburgh, Scotland)|May 23, 2008
Anti-PGL-Tb1 responses as an indicator of the immune restoration syndrome in HIV-TB patientsN Simonney, G Dewulf, J-L Herrmann, et al.
Infectious Diseases Now|February 16, 2022
Factors associated with hospital admission and adverse outcome for COVID-19: Role of social factors and medical careA-L Beaumont, D Vignes, R Sterpu, et al.
HIV Medicine|August 9, 2011
The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysisM Murray, R S Hogg, V D Lima, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 8, 2013
The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy eraA Mocroft, H J Furrer, J M Miro, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
HIV Medicine|December 4, 2018
Does region of origin influence the timing and outcome of first-line antiretroviral therapy in France?C Gatey, A Brun, G Hamet, et al.
International Journal of STD & AIDS|March 27, 2014
Risk factors for adherence failure in HIV-infected sub-Saharan migrants living in France and travelling back to their native countryS Abgrall, L Fugon, N Lélé, et al.
The Journal of Antimicrobial Chemotherapy|June 4, 2011
Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavirT Bommenel, O Launay, J L Meynard, et al.
HIV Medicine|November 5, 2024
Viral rebound on antiretroviral therapy in France according to region of origin, sex, and HIV acquisition group. Results from the French Hospital Database on HIV (ANRS CO4-FHDH)S Abgrall, H Selinger-Leneman, E Lanoy, et al.
Tuberculosis (Edinburgh, Scotland)|May 23, 2008
Anti-PGL-Tb1 responses as an indicator of the immune restoration syndrome in HIV-TB patientsN Simonney, G Dewulf, J-L Herrmann, et al.
Infectious Diseases Now|February 16, 2022
Factors associated with hospital admission and adverse outcome for COVID-19: Role of social factors and medical careA-L Beaumont, D Vignes, R Sterpu, et al.
HIV Medicine|August 9, 2011
The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysisM Murray, R S Hogg, V D Lima, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 8, 2013
The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy eraA Mocroft, H J Furrer, J M Miro, et al.
Pageof 3